C hronic hepatitis C (CHC) and alcoholic liver disease (ALD) are major causes of chronic liver disease (CLD), but nonalcoholic fatty liver disease (NAFLD) has now become the most common cause of CLD.
C hronic hepatitis C (CHC) and alcoholic liver disease (ALD) are major causes of chronic liver disease (CLD), but nonalcoholic fatty liver disease (NAFLD) has now become the most common cause of CLD. 1 Coffee consumption has been inversely associated with CLD severity, 2 but studies were mainly conducted in CHC, and fewer studies have been done in other etiologies. We examined the association between coffee consumption and CLD with and without cirrhosis by underlying etiology in African Americans, Native Hawaiians, Japanese Americans, Latinos, and whites in the Multiethnic Cohort (MEC).
Methods
The MEC is a prospective study of >215,000 participants aged 45-75 years at enrollment between 1993 and 1996. The study design, baseline characteristics, and outcome ascertainments have been described previously. 3, 4 For this study, we used a nested casecontrol study derived from MEC participants who were enrolled in the Medicare fee-for-service and completed questionnaires on coffee intake and confounders (n ¼ 95,197). As previously described, 5 CLD and cirrhosis cases were identified by using Medicare claims between 1999 and 2012. International Classification of Diseases, 9th Revision, Clinical Modification codes, body mass index (BMI), alcohol intake, and history of diabetes mellitus were used to classify cases into etiologic groups. 5 The 5385 CLD cases were identified as ALD (n ¼ 1112), NAFLD (n ¼ 2786), CHC (n ¼ 606), chronic hepatitis B (CHB) (n ¼ 165), other (n ¼ 357), and cryptogenic (n ¼ 359). Controls were selected from the eligible participants without CLD and were individually matched to cases (15:1) by age, sex, ethnicity, and length of fee-for-service enrollment.
Coffee drinking data were obtained by using a quantitative food-frequency questionnaire. 3 A calibration study of the quantitative food-frequency questionnaire conducted by using three 24-hour recalls from a random subsample revealed an excellent correlation coefficient (0.72) for coffee consumption. Coffee intake was categorized into never, <1 cup daily, 1 cup daily, 2-3 cups daily, and 4 cups daily. Associations of coffee intake with CLD were quantified by odds ratio and 95% confidence interval by using logistic models conditioned on the sets defined by matching variables and adjusted for education, BMI, diabetes, smoking status, and alcohol intake. Tests for trend were performed by entering the ordinal values representing categories of exposures as continuous variables in the models. Analyses were conducted by using SAS 9.3 (SAS Institute Inc, Cary, NC).
Results
The median age at cohort entry of the cases and controls was 61 years, and 44% were male. The ethnicity breakdown was 12% African Americans, 38% Japanese Americans, 5% Native Hawaiians, 22% Latinos, and 23% whites.
The risks for CLD associated with ALD (P trend ¼ .0015), NAFLD (P trend ¼ .0001), and CHC (P trend ¼ .0241) were reduced with increasing coffee consumption ( Table 1 ). The associations of coffee with ALD (P trend < .0001) and CHC (P trend ¼ .0215) were mainly observed in those with cirrhosis. Interestingly, with NAFLDassociated CLD, a significant trend was seen for both cirrhosis (P trend ¼ .0484) and non-cirrhosis cases (P trend ¼ .0018). No association was found between coffee drinking and CLD or cirrhosis caused by other etiologies (eg, CHB). There was no evidence that the Include cases with both chronic hepatitis C virus and chronic hepatitis B virus. b Include hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson's disease, human immunodeficiency virus, and autoimmune hepatitis. c OR stratified by matching factors (age, sex, race/ethnicity, and length of fee-for-service enrollment) and adjusted for education, BMI, diabetes, smoking status, and alcohol intake.
coffee associations with ALD, NAFLD, and CHC varied by ethnicity (P heterogeneity .20).
Discussion
In this study with multiple ethnic groups, coffee drinking is associated with reduced risk of NAFLD-, CHC-, and ALD-associated CLD. In CHC and ALD, coffee intake was mainly associated with a decrease in risk of CLD with cirrhosis. In NAFLD, it was associated with decreased risk of CLD both with and without cirrhosis.
Our findings support data from studies 2 showing the effect of coffee on liver enzyme reduction and the association of increased coffee consumption with reduced histologic activity, in particular fibrosis in CHC. Our data also suggest a possible effect of coffee intake on the fibrosis process in ALD and CHC and an effect of coffee on multiple pathways in NAFLD, possibly including inflammatory, steatotic, and fibrotic processes. The effect of coffee on fibrosis may be mediated by adenosine receptors. 6 It is possible that coffee constituents have a direct effect on steatosis or steatohepatitis pathways.
Fewer studies have been conducted to assess the effects of coffee consumption in ALD and NAFLD in comparison with CHC.
2 A meta-analysis suggested a protective association for ALD and CHC-related cirrhosis, 7 whereas another meta-analysis only showed the association in patients with alcoholic cirrhosis. 8 The study limitations include the likely underestimation of the true prevalence of NAFLD and possibly other etiologies because of the lack of biochemical and imaging testing and the use of self-reported coffee intake at baseline, which is subject to measurement error. The strengths include its large size, population-based design, validated questionnaire, inclusion of 5 ethnic, mostly understudied populations, and information on important confounders.
In conclusion, coffee drinking is associated with reduced CLD risk, particularly for NAFLD, ALD, and CHC, including cirrhosis. We propose that randomized controlled trials should be entertained, in particular in NAFLD patients where coffee consumption seems to affect the entire disease process and no treatments are currently available.
